ReviewTherapeutic advances in chronic disease2021
Review of current and future therapeutics in ABPA.
Review in Therapeutic advances in chronic disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Pooled it
- Development of a mobile app for the evaluation of patients with chronic rhinosinusitis.Brazilian journal of otorhinolaryngologyPooled it
- The association between different regimens of glucocorticoid and antifungal treatment with the prognosis of allergic bronchopulmonary aspergillosis: a retrospective cohort study.Annals of medicine · 2026Article
- A Role for Non-Canonical Caspases in Fungal Allergic Airway Disease.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Article
- Allergic Fungal Rhinosinusitis Diagnosis, Management, Associated Conditions, Pathophysiology, and Future Directions: Summary of a Multidisciplinary Workshop.International forum of allergy & rhinology · 2025Review
- Asthma and respiratory comorbidities.The Journal of allergy and clinical immunology · 2025Review
- Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016-2022.PloS one · 2025Article
- Clinical characteristics and risk factors analysis of allergic bronchopulmonary aspergillosis combined with bronchiectasis.Frontiers in medicine · 2025Article
- PANoptosis opens new treatment options for allergic bronchopulmonary aspergillosis.The journal of allergy and clinical immunology. Global · 2024Article
- Allergic Bronchopulmonary Aspergillosis (ABPA) in the Era of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators.Journal of fungi (Basel, Switzerland) · 2024Review
- ABPA sans asthma: an entity to remember.BMJ case reports · 2022Article
- Successful management of recurrent allergic bronchopulmonary aspergillosis after changing from mepolizumab to dupilumab: A case report.Respiratory medicine case reports · 2022Article
- Allergic Bronchopulmonary Aspergillosis with an Atypical Mass-Like Presentation.Case reports in pulmonology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Allergic bronchopulmonary aspergillosis is an allergic pulmonary condition caused by hypersensitivity to antigens of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.